HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: JME-08-0071v1 41/5/251    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Peri, A. Articles by Serio, M. Search for Related Content PubMed PubMed Citation Articles by Peri, A. Articles by Serio, M.

Endocrine Unit, Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel Therapies (DENOThe), University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy

(Correspondence should be addressed to A Peri; Email: a.peri{at}dfc.unifi.it)

	Abstract

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
The endocrine and the nervous system are closely correlated throughout life, starting from the embryo and until the late stages of life. Alzheimer's disease (AD) is the most common neurodegenerative disease associated with ageing. Unfortunately, an effective way to prevent or to cure this disease does not exist, so far. There is evidence that estrogens exert neuroprotective properties, although their efficacy against AD is still a matter of debate. In 2000 a new neuroprotective gene, i.e. seladin-1 (for SELective AD INdicator-1) was identified and found to be down regulated in AD vulnerable brain regions. Seladin-1 inhibits the activation of caspase-3, a key modulator of apoptosis. This protein has also enzymatic activity. In fact, it has been demonstrated that the seladin-1 gene encodes 3-β-hydroxysterol -24-reductase, which catalyzes the synthesis of cholesterol from desmosterol. In recent years, it has been demonstrated that an appropriate amount of membrane cholesterol determines the generation of a barrier against toxic insults and prevents the production of β-amyloid, the histopathological hallmark of AD. This review will summarize the studies that have been focused on the characterization of the biological properties of seladin-1 since its first identification. In particular, the relationship between seladin-1-mediated neuroprotection and estrogens, IGF1 and thyroid hormones, will be described and discussed.

	Introduction

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
A tight interplay between the endocrine and the nervous system occurs throughout life, starting from the embryo. Hormones play a role in promoting brain development at the beginning of life and contribute to maintain brain homeostasis until the senile age. With regard to the latter issue, although the neuroprotective role of estrogen is well established, their usefulness in preventing or treating the most common neurodegenerative disease associated with ageing, i.e. Alzheimer's disease (AD), is still a debated question. The identification of the seladin-1 (SELective AD INdicator-1) gene as a novel neuroprotective factor opened a new scenario on the complex molecular network involving the endocrine and the nervous system. Seladin-1 is the human homolog of the plant DIMINUTO/DWARF1 gene, primarily described in Arabidopsis thaliana (Takahashi et al. 1995, Klahre et al. 1998). This review will summarize the experimental data obtained in the last few years regarding the characterization of the biological properties of seladin-1 and the relationship of this protein with the endocrine system.

	The identification and characterization of seladin-1

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
The seladin-1 gene was first identified in 2000 by using a differential mRNA display approach to identify genes that were differentially expressed in selective vulnerable brain regions in AD (Greeve et al. 2000), such as the hippocampus, the amygdala, the inferior temporal cortex and the entorhinal cortex (Selkoe 2001). Among the over 30 genes differentially expressed in AD vulnerable brain regions versus unaffected areas, the authors identified a novel cDNA (thereafter named seladin-1) with a markedly reduced expression in the inferior temporal cortex of AD patients compared with the frontal cortex, obtained shortly postmortem. Conversely, seladin-1 was evenly expressed in the brain of unaffected individuals. Later on, we demonstrated that this gene is abundantly expressed in stem cells, whereas the level of expression markedly decreases when these cells are induced to differentiate into mature neurons (Benvenuti et al. 2006). This finding led us to hypothesize that defective seladin-1 expression detected in AD vulnerable brain regions might be linked to an impaired neuronal stem cell compartment, that could be a potential risk factor to develop this disease. The seladin-1 gene (GenBank accession number AF261758) spans 46.4 kb, maps to chromosome 1p31.1-p33, and comprises nine exons and eight introns; it encodes an open reading frame of 516 amino acid residues. Seladin-1 is located in the endoplasmic reticulum and, although to a lesser extent, in the Golgi apparatus (Greeve et al. 2000).

Apart from the brain, seladin-1 expression has been also detected in many different organs, including endocrine organs, such as the adrenal gland (Greeve et al. 2000, Sarkar et al. 2001, Luciani et al. 2004, Battista et al. 2007), the pituitary gland (Greeve et al. 2000, Luciani et al. 2005), the thyroid gland (Greeve et al. 2000), the prostate (Dong et al. 2005, Hendriksen et al. 2006, Biancolella et al. 2007, Bonaccorsi et al. 2008), the ovary (Greeve et al. 2000, Fuller et al. 2005), and the testis (Greeve et al. 2000).

With regard to its biological effects, seladin-1 was originally found to confer resistance against β-amyloid and oxidative stress-induced apoptosis and to effectively inhibit the activation of caspase-3, a key mediator of the apoptotic process. Interestingly, in PC12 cells (rat adrenal pheochromocytoma) that were selected for resistance against β-amyloid toxicity, the level of expression of seladin-1 was remarkably high (Greeve et al. 2000). A subsequent study demonstrated that the down-regulation of seladin-1 expression in vulnerable AD brain areas is paralleled by an increase in the amount of hyperphosphorylated tau, a protein component of neurofibrillary tangles (Iivonen et al. 2002). The anti-apoptotic effect of seladin-1 has also been associated to a more aggressive behavior and to a defective response to pharmacological treatment in human neoplasia. For instance, in pituitary tumors we have detected markedly higher levels of expression of seladin-1 in non-functioning adenomas compared with GH-secreting adenomas. Accordingly, the somatostatin analogue octreotide was able to activate caspase-3 and to induce apoptosis in primary cell cultures obtained from GH-secreting adenomas, but not from non-functioning adenomas (Luciani et al. 2005). Our conclusion was that seladin-1 may be viewed as one of the factors that confer resistance to pharmacological intervention in this subset of pituitary tumors. In another study, higher levels of expression of seladin-1 in melanoma metastases compared with primary tumors, were associated with resistance against oxidative stress-induced apoptosis (Di Stasi et al. 2005). Very recently, it has been demonstrated that the ability of seladin-1 to protect against apoptosis elicited by oxidative stress may be related to the scavenger activity of this protein (Lu et al. 2008). The authors of the study showed that intracellular generation of reactive oxygen species (ROS) in response to H₂O₂ was diminished in embryonic mouse fibroblasts expressing seladin-1, compared with cells in which the expression had been abolished, thus suggesting a ROS-scavenging activity for this protein. This hypothesis was validated by the observation that intact seladin-1 was associated with high H₂O₂-scavenging activity, whereas an N-terminal deletion caused the loss of this activity. Although the literature unequivocally recognizes the anti-apoptotic property of seladin-1, one single study addressed this protein as a key mediator of Ras-induced senescence (Wu et al. 2004). In this study it was shown that, following oncogenic and oxidative stress, seladin-1 binds p53 in fibroblasts and displaces E3 ubiquitin ligase Mdm2 from p53, thus resulting in p53 accumulation. Ablation of seladin-1 caused the bypass of Ras-induced senescence, and allowed Ras to transform cells. Wild-type seladin-1 cells, but not mutants that disrupt its association with either p53 or Mdm2, were able to suppress the transformed phenotype. These results showed an unanticipated role for seladin-1 in integrating cellular response to oncogenic and oxidative stress. A very recent publication has possibly clarified the apparent discrepancy between the role of seladin-1 in preventing apoptosis on the one hand, and its association with increased levels of p53 on the other hand. Neuroblastoma cells were subjected to acute or chronic oxidative stress. Following acute stress, seladin-1 expression increased and the over expression conferred resistance to H₂O₂-induced toxicity. Conversely, chronic exposure to oxidative stress diminished the expression of seladin-1, but the protective effect was maintained. In fact, reduced seladin-1 levels prevented apoptosis in a p53-dependent manner, via increased p53 ubiquitination and degradation (Kuehnle et al. 2008).

	Seladin-1 as an enzyme

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
A fundamental step forward in unraveling the biological properties of seladin-1 was represented by the demonstration that this protein has also a specific enzymatic activity, which was found to be markedly reduced in desmosterolosis, a rare autosomal recessive disorder characterized by multiple congenital anomalies (FitzPatrick et al. 1998). Patients with desmosterolosis have elevated plasma levels of the cholesterol precursor desmosterol and this abnormality suggested a deficiency of the enzyme 3-β-hydroxysterol -24-reductase (DHCR24), which catalyzes the reduction of the ²⁴ double bond in desmosterol to produce cholesterol (Fig. 1). Waterham and colleagues identified the human DHCR24 cDNA, which appeared identical to seladin-1 (Waterham et al. 2001). DHCR24 activity was confirmed in vitro by enzymatic assay following heterologous expression of the DHCR24 cDNA in Saccharomyces cerevisiae. Conversely, in constructs containing mutant DHCR24 alleles from patients with desmosterolosis the conversion from desmosterol into cholesterol was absent or markedly reduced. Desmosterolosis belongs to a group of several inherited disorders, linked to enzyme defects in the cholesterol biosynthetic pathway at the post-squalene level, which have been described in recent years (Herman 2003). These genetic diseases are characterized by major developmental malformations and in most cases determine severe neuropsychological alterations, suggesting an important role for cholesterol in brain homeostasis.

The identification of the 4 allelic variant of the apolipoprotein E as a major genetic risk factor for AD suggests a role for cholesterol in the pathogenesis of this disease, although this is still an open and controversial issue, at present. The published literature is divided between those who support the idea that cholesterol may favor the onset of the disease and those who, on the contrary, believe that cholesterol may play a protective role against AD. In particular, on the one hand some reports showed that elevated cholesterol levels increase β-amyloid formation in in vitro systems and in animal models of AD (Yanagisawa 2002, Herman 2003, Puglielli et al. 2003). Accordingly, epidemiological studies suggest that statin therapy may provide protection against AD, although the clinical benefit of statins might be also due to their cholesterol-independent effects on cerebral circulation and inflammation (Reiss et al. 2004). Furthermore, it has to be said that most of the commercially available statins do not cross the blood-brain barrier. This observation appears to be in agreement with the opinion of those who, on the other hand, support the idea that cholesterol may actually be good for the brain. It has to be considered that the central nervous system contains as much as 25% of the total amount of unesterified cholesterol in the entire body, which is mostly produced via local de novo synthesis. Keeping this in mind, it is not surprising that several studies pointed out the fact that the intracellular content of cholesterol, particularly the amount contained in the cell membrane, should be addressed much more than the plasma levels (Yanagisawa 2002). In this new scenario, the dichotomy between the view of cholesterol as a neurotoxic or a neuroprotective factor might thus be only apparent. If cell cholesterol is considered, an appropriate amount in the cell membrane would create a barrier against toxic insults, whereas a cholesterol-depleted membrane would ease the interaction with toxic factors such as β-amyloid, which may generate for instance an anomalous number of calcium channels leading to the accumulation of toxic levels of calcium (Fig. 2; Arispe & Doh 2002). Accordingly, reduced membrane lipids in the cortex of AD transgenic mice have been detected (Yao et al. 2008). We have very recently provided evidence that over expression of seladin-1, as well as PEG-cholesterol treatment, increases resistance to β-amyloid toxicity and prevents calcium influx in neuroblastoma cells, whereas the exposure to a selective inhibitor of DHCR24 blunts these effects, similarly to cholesterol depletion with methyl-β-cyclodextrin (Cecchi et al. 2008). The amount of cell cholesterol may also affect amyloidogenesis. It has been shown that in membranes from AD patients, or in rodent hippocampal neurons with a moderate reduction of membrane cholesterol, the interaction between the amyloidogenic enzyme β-secretase and amyloid precursor protein (APP) is facilitated, thus leading to elevated production of β-amyloid (Fig. 3; Abad-Rodriguez et al. 2004). Similarly, seladin-1 deficient mouse brains had reduced levels of cholesterol, that were associated with increased cleavage of APP by β-secretase and high levels of β-amyloid. Conversely, seladin-1 over expression increased cholesterol levels and reduced APP processing in neuroblastoma cells (Crameri et al. 2006). These results suggest that loss of membrane cholesterol in neurons contributes both to increased membrane interaction with β-amyloid and to excessive amyloidogenesis in AD. Thus, the reduced expression of seladin-1 in AD vulnerable regions is in keeping with the ‘membrane integrity’ theory. Overall, the experimental findings on the neuroprotective role of seladin-1 are clearly in favor of the hypothesis that an optimal amount of cell cholesterol may be critical for brain homeostasis. In this view, the role of statins in neuroprotective strategies might be limited to their vasoprotective and/or anti-inflammatory effects.

	Seladin-1 as a new effector of estrogen receptor (ER)-mediated neuroprotection

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
There is well established in vitro evidence that estrogens exert neurotropic and neuroprotective effects by stimulating the expression of neurotropins and cell-survival factors, enhancing synaptic plasticity, and acting as an antioxidant factor (Behl 2003, Maggi et al. 2004, Turgeon et al. 2006). AD is more common in women and it is known that decreased estrogen levels after menopause are a risk factor for the disease (Paganini-Hill & Henderson 1994). Thus, estrogen therapy has been considered a rationale option for the treatment of this disease. Despite the lack of general consensus, several studies indicated that estrogen treatment may decrease the risk or delay the onset of AD in post-menopausal women (Fillit 2002). Although the data from the Women's Health Initiative Memory Study trial indicated that hormone replacement therapy (HRT) has no benefit (Rapp et al. 2003, Shumaker et al. 2003), it has to be considered that a number of factors may determine the efficacy of estrogens or HRT, such as age, the menopausal status, the route of administration and the dose, the starting cognitive function, and the presence of pre-existing risk factors (i.e. smoking, apolipoprotein E genotype; MacLusky 2004, Turgeon et al. 2006). In particular, there seems to be a critical time for estrogen treatment. In fact, early and prolonged therapy has been found to produce the maximum benefit in terms of reduced risk for AD (Resnick & Henderson 2002, Zandi et al. 2002). In addition, estrogen therapy is not the same as HRT and the type of progestogen used may determine the outcome of the therapeutic intervention (Schumacher et al. 2007). The neuroprotective role of the selective ER modulators (SERMs) has been less extensively investigated. Nonetheless, a neuroprotective effect of tamoxifen and raloxifene has been observed (Dhandapani & Brann 2002) and a beneficial role of tamoxifen and raloxifene against β-amyloid toxicity has been demonstrated in rat neurons (O'Neill et al. 2004a,b). The Multiple Outcomes of Raloxifene Evaluation trial evaluated the cognitive function in more than 5000 women with osteoporosis who were assigned to receive raloxifene (60 mg or 120 mg) or placebo daily for 3 years. Compared with those taking placebo, women receiving 120 mg/day of raloxifene had a 33% lower risk of mild cognitive impairment and somewhat lower risks of AD and any cognitive impairment (Yaffe et al. 2005).

In order to establish whether seladin-1 may be involved in estrogen-mediated neuroprotection, we have taken advantage of a unique cell model of human fetal neuronal precursor, that expresses both ER and β (Barni et al. 1999). These fetal neuroepithelial cells (FNC) are long-term cell cultures from human fetal (8-12 weeks of gestational age) olfactory epithelium, that were established, cloned and propagated by Vannelli et al. (1995). FNC cells express both neuronal and olfactory markers that are typical of maturing olfactory receptor neurons, are electrically excitable and following exposure to a number of different aromatic chemicals show a specific increase in intracellular cAMP, indicating some degree of functional maturity (Vannelli et al. 1995). Thus, FNC cells appear to originate from the stem cell compartment that generates mature olfactory receptor neurons.

Preliminarily, we confirmed the protective role of estrogens/SERMs in the brain. In fact, 17β-estradiol was able to stimulate cell proliferation (100 pM and 100 nM) and to effectively counteract β-amyloid- and H₂O₂-mediated toxicity (100 pM, 1-10-100 nM; Benvenuti et al. 2005). In agreement with 17β-estradiol, also the SERM tamoxifen (100 pM-100 nM) effectively protected FNC cells from the toxic effects of β-amyloid, whereas partially different results were observed with raloxifene. In fact, cell viability after exposure to β-amyloid was preserved at low concentrations of raloxifene (100 pM and 1 nM). Conversely, 10 and 100 nM did not exert protective effects. In addition, we demonstrated that the protective action of estrogens in FNC cells was associated with a counteracting effect against β-amyloid-induced apoptosis, as demonstrated by the strong inhibition of the activation of caspase-3. In the same study, we also demonstrated that FNC cells constitutively express seladin-1 and that 17β-estradiol (10 pM-100 nM), tamoxifen (1 nM), raloxifene (1 nM), and a selective ER agonist (propylpyrazole-triol; 10 nM) significantly increased the amount of mRNA. However, a selective ERβ agonist (diarylpropionitrile; 10 nM) did not affect seladin-1 expression, whereas higher concentrations of raloxifene (10-100 nM) determined a marked reduction. These findings, and in particular the parallelism between the concentrations of raloxifene that conferred neuroprotection on the one hand, and stimulated seladin-1 expression on the other hand, led us to hypothesize that seladin-1 might be a mediator of the neuroprotective effects of estrogens/SERMs.

Noteworthy, this hypothesis was supported by an additional very recent study. In fact, we demonstrated that, upon silencing seladin-1 expression by small interfering RNA (siRNA) methodology, the protective effect against β-amyloid and oxidative stress toxicity exerted by 17β-estradiol was lost (Fig. 4). The specificity of these results was validated by the observation that in cells exposed to control siRNA the protective effects of 17β-estradiol were maintained (Luciani et al. 2008). Furthermore, a computer assisted analysis revealed the presence of half-palindromic estrogen responsive elements (EREs) upstream of the coding region of the seladin-1 gene. A region spanning around 1500 bp was cloned in a luciferase reporter vector, which was transiently co-transfected with the ER in CHO cells. The exposure to 17β-estradiol, as well as to raloxifene and tamoxifen increased luciferase activity, thus suggesting a functional role for the half EREs of the seladin-1 gene. Overall, these additional data provided a direct demonstration that seladin-1 is a fundamental mediator of the neuroprotective effects of estrogens.

	Seladin-1 as a mediator of the pro- survival effects of IGF1

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

	Seladin-1 as a mediator of the effects of thyroid hormones (TH) in promoting brain development

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

	Conclusions

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

	Declaration of interest

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

	Funding

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
The experimental studies presented in this review were partially supported by a grant from Ente Cassa di Risparmio di Firenze and by a grant from Ministero dell'Istruzione, dell'Università e della Ricerca.

	Acknowledgements

 
The authors wish to thank the following collaborators at the Department of Clinical Physiopathology, University of Florence, Italy, for their tireless support: Drs Susanna Benvenuti, Paola Luciani, Ilaria Cellai, Cristiana Deledda, Silvana Baglioni, Giovanna Danza, Fabiana Rosati, Matteo Morello, Francesca Dichiara, Corinna Giuliani, Stefano Giannini, and Anna Pezzatini. The support provided by colleagues at the Department of Anatomy, Histology, and Forensic Medicine, the Department of Biochemical Sciences, the Department of Physiological Sciences, the Department of Haematology, the Institute of Dermatology and Venereology at the University of Florence and at the Careggi University Hospital, Florence, and the continuative collaboration with the Institute of Endocrine Sciences and the Laboratory of Developmental Neuroendocrinology, Department of Endocrinology, Centre of Excellence on Neurodegenerative Diseases, University of Milan, and the Department of Endocrinology and Metabolism, University of Pisa are also acknowledged. The authors wish to thank Eli Lilly for kindly providing raloxifene.

	References

Top Abstract Introduction The identification and... Seladin-1 as an enzyme Seladin-1 as a new... Seladin-1 as a mediator... Seladin-1 as a mediator... Conclusions Declaration of interest Funding References

 
Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B & Dotti CG 2004 Neuronal membrane cholesterol loss enhances amyloid peptide generation. Journal of Cell Biology 167 953-960.[Abstract/Free Full Text]

Arispe N & Doh M 2002 Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB Journal 16 1526-1536.[Abstract/Free Full Text]

Barni T, Maggi M, Fantoni G, Granchi S, Mancina R, Gulisano M, Marra F, Macorsini E, Luconi M, Rotella C et al. 1999 Sex steroids and odorants modulate gonadotropin-releasing hormone secretion in primary cultures of human olfactory cells. Journal of Clinical Endocrinology and Metabolism 84 4266-4273.[Abstract/Free Full Text]

Battista MC, Roberge C, Otis M & Gallo-Payet N 2007 Seladin-1 expression in rat adrenal gland: effect of adrenocorticotropic hormone treatment. Journal of Endocrinology 192 53-66.[Abstract/Free Full Text]

Behl C 2003 Estrogen can protect neurons: modes of action. Journal of Steroid Biochemistry and Molecular Biology 83 195-197.[Web of Science]

Benvenuti S, Luciani P, Vannelli GB, Gelmini S, Serio M & Peri A 2005 Estrogen and SERMs exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered anti-apoptotic gene, in human neuroblast long-term cell cultures. Journal of Clinical Endocrinology and Metabolism 90 1775-1782.[Abstract/Free Full Text]

Benvenuti S, Saccardi R, Luciani P, Urbani S, Deledda C, Cellai I, Francini F, Squecco R, Rosati F, Danza G et al. 2006 Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease - related gene seladin-1. Experimental Cell Research 312 2592-2604.[Web of Science][Medline]

Benvenuti S, Luciani P, Cellai I, Deledda C, Baglioni S, Saccaridi R, Urbani S, Francini F, Squecco R, Giuliani C et al. 2008 Thyroid hormones promote cell differentiation and up-regulate the expression of the seladin-1 gene in in vitro models of human neuronal precursors. Journal of Endocrinology 197 437-446.[Abstract/Free Full Text]

Biancolella M, Valentini A, Minella D, Secchione L, D'Amico F, Chillemi G, Gravina P, Bueno S, Prosperino G, Desideri A et al. 2007 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Investigational New Drugs 25 491-497.[CrossRef][Web of Science][Medline]

Bonaccorsi L, Luciani P, Nesi G, Mannucci E, Deledda C, Dichiara F, Paglierini M, Rosati F, Masieri L, Serni S et al. 2008 Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Laboratory Investigation 88 1049-1056.[CrossRef][Web of Science][Medline]

Brooker GJ, Kalloniatis M, Russo VC, Murphy M, Werther GA & Bartlett PF 2000 Endogenous IGF-I regulates the neuronal differentiation of adult stem cells. Journal of Neuroscience Research 59 332-341.[CrossRef][Web of Science][Medline]

Calzà L, Giardino L & Aloe L 1997 Thyroid hormone regulates NGF content and p75LNGFR expression in the basal forebrain of adult rats. Experimental Neurology 143 196-206.[CrossRef][Web of Science][Medline]

Cecchi C, Rosati F, Pensalfini A, Formigli L, Nosi D, Liguri G, Dichiara F, Morello M, Danza G, Pieraccini G et al. 2008 Seladin-1/DHCR24 protects neuroblastoma cells against abeta toxicity by increasing membrane cholesterol content. Journal of Cellular and Molecular Medicine(Epub ahead of print)

Clouse SD & Sasse JM 1998 BRASSINOSTEROIDS: essential regulators of plant growth and development. Annual Review of Plant Physiology and Plant Molecular Biology 49 427-451.[CrossRef][Web of Science]

Crameri A, Biondi E, Kuehnle K, Lütjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD & Mohajeri MH 2006 The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO Journal 25 432-443.[CrossRef][Web of Science][Medline]

Dhandapani KM & Brann DW 2002 Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biology of Reproduction 67 1379-1385.[Abstract/Free Full Text]

Dong Y, Zhang H, Gao AC, Marshall JR & Ip C 2005 Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Molecular Cancer Therapeutics 4 1047-1055.[Abstract/Free Full Text]

Fillit HM 2002 The role of hormone replacement therapy in the prevention of Alzheimer's disease. Archives of Internal Medicine 162 1934-1942.[Abstract/Free Full Text]

FitzPatrick DR, Keeling JW, Evans MJ, Kan AE, Bell JE, Porteous ME, Mills K, Winter RM & Clayton PT 1998 Clinical phenotype of desmosterolosis. American Journal of Medical Genetics 75 145-152.[CrossRef][Web of Science][Medline]

Fuller PJ, Alexiadis M, Jobling T & McNeilage J 2005 Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours. Clinical Endocrinology 63 111-115.[CrossRef][Medline]

Giannini S, Benvenuti S, Luciani P, Manuelli C, Cellai I, Deledda C, Pezzatini A, Vannelli GB, Maneschi E, Rotella CM et al. 2008 Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor seladin-1. Journal of Endocrinology 198 523-532.[Abstract/Free Full Text]

Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B & Nitsch RM 2000 The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. Journal of Neuroscience 20 7345-7352.[Abstract/Free Full Text]

Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE et al. 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. New England Journal of Medicine 341 549-555.[Abstract/Free Full Text]

Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J & Jenster G 2006 Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Research 66 5012-5020.[Abstract/Free Full Text]

Herman GE 2003 Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Human Molecular Genetics 12 R75-R88.[Abstract/Free Full Text]

Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, Salminen A, Helisalmi S & Soininen H 2002 Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience 113 301-310.[CrossRef][Medline]

Klahre U, Noguchi T, Fujioka S, Takatsuto S, Yokta T, Nomura T, Yoshida S & Chua NH 1998 The Arabidopsis DIMINUTO/DWARF1 gene encodes a protein involved in steroid synthesis. Plant Cell 10 1677-1690.[Abstract/Free Full Text]

König S & Neto VM 2002 Thyroid hormone actions on neural cells. Cellular and Molecular Neurobiology 22 517-544.[CrossRef][Web of Science][Medline]

Kuehnle K, Crameri A, Kälin RE, Luciani P, Benvenuti S, Peri A, Ratti F, Rodolfo M, Kulic L, Heppner FL et al. 2008 Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress. Molecular and Cellular Biology 28 539-550.[Abstract/Free Full Text]

Lavado-Autric R, Auso E, Garcia-Velasco JV, del Carmen Arufe M, Escobar del Rey F, Berbel P & Morreale de Escobar G 2003 Early maternal hypothyroxinemia alters histogenesis and cerebral cortex cytoarchitecture of the progeny. Journal of Clinical Investigation 111 1073-1082.[CrossRef][Web of Science][Medline]

Lu X, Kambe F, Cao X, Kozaki Y, Kaji T, Ishii T & Seo H 2008 DHCR24 is a hydrogen peroxide scavenger, protecting cells from oxidative-stress-induced apoptosis. Endocrinology 149 3267-3273.[Abstract/Free Full Text]

Luciani P, Ferruzzi P, Arnaldi G, Crescioli C, Benvenuti S, Valeri A, Greeve I, Serio M, Mannelli M & Peri A 2004 Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. Journal of Clinical Endocrinology and Metabolism 89 1332-1339.[Abstract/Free Full Text]

Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani G, Cellai I, Ammannati F, Spada A et al. 2005 Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 90 6156-6161.[Abstract/Free Full Text]

Luciani P, Deledda C, Rosati F, Benvenuti S, Cellai I, Dichiara F, Morello M, Vannelli GB, Danza G, Serio M et al. 2008 Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology 149 4256-4266.[Abstract/Free Full Text]

MacLusky NJ 2004 Estrogen and Alzheimer's disease: the apolipoprotein connection. Endocrinology 145 3062-3064.[Free Full Text]

Maggi A, Ciana P, Belcredito S & Vegeto E 2004 Estrogens in the nervous system: mechanisms and nonreproductive functions. Annual Review of Physiology 66 291-313.[CrossRef][Web of Science][Medline]

Matthews CC & Feldman EL 1996 Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. Journal of Cellular Physiology 166 323-331.[CrossRef][Web of Science][Medline]

Mazerbourg S, Callebaut I, Zapf J, Mohan S, Overgaard M & Monget P 2004 Up date on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and in vivo. Growth Hormone and IGF Research 14 71-84.[CrossRef]

Mendez P, Azcoitia I & Garcia-Segura LM 2005 Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analyzing neuroprotective mechanisms. Journal of Endocrinology 185 11-17.[Abstract/Free Full Text]

Mendez P, Wandosell F & Garcia-Segura LM 2006 Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: cellular and molecular mechanisms. Frontiers in Neuroendocrinology 27 391-403.[CrossRef][Web of Science][Medline]

Mirza R, Hayasaka S, Takagishi Y, Kambe F, Ohmori S, Maki K, Yamamoto M, Murakami K, Kaji T, Zadworny D et al. 2006 DHCR24 gene knockout mice demonstrate lethal dermopathy with differentiation and maturation defects in the epidermis. Journal of Investigative Dermatology 126 638-647.[CrossRef][Web of Science][Medline]

Mirza R, Hayasaka S, Kambe F, Maki K, Kaji T, Murata Y & Seo H 2008 Increased expression of aquaporin-3 in the epidermis of DHCR24 knockout mice. British Journal of Dermatology 158 679-684.[CrossRef][Web of Science][Medline]

Morreale de Escobar G, Obregón MJ & Escobar del Rey F 2004 Role of thyroid hormone during early brain development. European Journal of Endocrinology 151 U25-U37.[Abstract]

O'Neill K, Chen S & Brinton RD 2004a Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Experimental Neurology 185 63-80.[CrossRef][Web of Science][Medline]

O'Neill K, Chen S & Brinton RD 2004b Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Experimental Neurology 188 268-278.[CrossRef][Web of Science][Medline]

Paganini-Hill A & Henderson VW 1994 Estrogen deficiency and risk of Alzheimer's disease in women. American Journal of Epidemiology 140 256-261.[Abstract/Free Full Text]

Patel AJ, Hayashi M & Hunt A 1987 Selective persistent reduction in choline acetyltransferase activity in basal forebrain of the rat after thyroid deficiency during early life. Brain Research 422 182-185.[CrossRef][Web of Science][Medline]

Peri A, Danza G & Serio H 2005 Seladin-1 as a target of estrogen receptor activation in the brain: a new gene for a rather old story? Journal of Endocrinological Investigation 28 285-293.[Web of Science][Medline]

Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, Zuodar G & Ceriello A 2006 Constant and intermittent high glucose enhances endothelial cells apoptosis through mitocondrial superoxide overproduction. Diabetes/Metabolism Research and Reviews 22 198-203.[CrossRef][Web of Science][Medline]

Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL & de Vijlder JJ 2003 Maternal hypothyroxinemia during early pregnancy and subsequent child development: a 3-year follow-up study. Clinical Endocrinology 59 282-288.[CrossRef][Medline]

Puglielli L, Tanzi RE & Kovacs DM 2003 Alzheimer's disease: the cholesterol connection. Nature Neuroscience 6 345-351.[CrossRef][Web of Science][Medline]

Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J et al. 2003 Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Journal of the American Medical Association 289 2663-2672.[Abstract/Free Full Text]

Reiss AB, Siller KA, Rahman MM, Chan ES, Ghiso J & de Leon MJ 2004 Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiology of Aging 25 977-989.[CrossRef][Web of Science][Medline]

Resnick SM & Henderson VW 2002 Hormone therapy and risk of Alzheimer disease. Journal of the American Medical Association 288 2170-2172.[Free Full Text]

Russo VC, Kobayashi K, Najdovska S, Baker NL & Werther GA 2004 Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system. Brain Research 1009 40-53.[CrossRef][Web of Science][Medline]

Russo VC, Gluckman PD, Feldman EL & Werther GA 2005 The Insulin-like growth factor system and its pleiotropic functions in brain. Endocrine Reviews 26 916-943.[Abstract/Free Full Text]

Sanchez-Ramos JR 2002 Neural cells derived from adult bone marrow and umbilical cord blood. Journal of Neuroscience Research 69 880-893.[CrossRef][Web of Science][Medline]

Santisteban P & Bernal J 2005 Thyroid development and effect on the nervous system. Reviews in Endocrine and Metabolic Disorders 6 217-228.[CrossRef]

Sarkar D, Imai T, Kambe F, Shibata A, Ohmori S, Siddiq A, Hayasaka S, Funahashi H & Seo H 2001 The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. Journal of Clinical Endocrinology and Metabolism 86 5130-5137.[Abstract/Free Full Text]

Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, Akwa Y, Rajkowski K & Baulieu EE 2007 Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocrine Reviews 28 387-439.[Abstract/Free Full Text]

Selkoe DJ 2001 Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 81 741-776.[Abstract/Free Full Text]

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN III, Assaf AR, Jackson RD et al. 2003 Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Journal of the American Medical Association 289 2651-2662.[Abstract/Free Full Text]

Di Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M, Chiodini E, Fiorentini S, Greeve I, Prinetti A, Rivoltini L et al. 2005 DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. International Journal of Cancer 115 224-230.[CrossRef][Web of Science][Medline]

Takahashi T, Gasch A, Nishizawa N & Chua NH 1995 The DIMINUTO gene of Arabidopsis is involved in regulating cell elongation. Genes and Development 9 97-107.[Abstract/Free Full Text]

Tomlinson DR & Gardiner NJ 2008 Glucose neurotoxicity. Nature Reviews. Neuroscience 9 36-45.[CrossRef][Web of Science][Medline]

Turgeon JL, Carr MC, Maki PM, Mendelsohn ME & Wise P 2006 Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocrine Reviews 27 576-605.

Vannelli GB, Ensoli F, Zonefrati R, Kubota Y, Arcangeli A, Becchetti A, Camici G, Barni T, Thiele CJ & Balboni GC 1995 Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors. Journal of Neuroscience 15 4282-4294.

Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, FitzPatrick DR, Kelley RI & Wanders RJ 2001 Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. American Journal of Human Genetics 69 685-694.[CrossRef][Web of Science][Medline]

Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spivak I, Moshkin O, Fridman E et al. 2003 Generation of viable cholesterol-free mice. Science 302 2087[Free Full Text]

Woodbury D, Schwarz EJ, Prockop DJ & Black IB 2000 Adult rat and human bone marrow stromal cells differentiate into neurons. Journal of Neuroscience Research 61 364-370.[CrossRef][Web of Science][Medline]

Wu C, Miloslavskaya I, Demontis S, Maestro R & Galaktionov K 2004 Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 432 640-645.[CrossRef][Medline]

Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, Ensrud K & Grady D 2005 Effect of raloxifene on prevention of dementia and cognitive imparirment in older women: the Multiple Outcome of Raloxifene Evaluation (MORE) randomized trial. American Journal of Psychiatry 162 683-690.[Abstract/Free Full Text]

Yanagisawa K 2002 Cholesterol and pathological processes in Alzheimer's disease. Journal of Neuroscience Research 70 361-366.[CrossRef][Web of Science][Medline]

Yao JK, Wengenack TM, Curran GL & Poduslo JF 2008 Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochemical ResearchIn Press

Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC & Cache County Memory Study Investigators 2002 Hormone replacement therapy and incidence of Alzheimer disease in older women. Journal of the American Medical Association 288 2123-2129.[Abstract/Free Full Text]

Received in final form 26 August 2008
Accepted 31 August 2008
Made available online as an Accepted Preprint 31 August 2008

This article has been cited by other articles:

				T. M. van Himbergen, S. Otokozawa, N. R. Matthan, E. J. Schaefer, A. Buchsbaum, M. Ai, L. J. H. van Tits, J. de Graaf, and A. F. H. Stalenhoef Familial Combined Hyperlipidemia Is Associated With Alterations in the Cholesterol Synthesis Pathway Arterioscler Thromb Vasc Biol, January 1, 2010; 30(1): 113 - 120. [Abstract] [Full Text] [PDF]

				L. A. Donehower Using Mice to Examine p53 Functions in Cancer, Aging, and Longevity Cold Spring Harb Perspect Biol, December 1, 2009; 1(6): a001081 - a001081. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: JME-08-0071v1 41/5/251    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Peri, A. Articles by Serio, M. Search for Related Content PubMed PubMed Citation Articles by Peri, A. Articles by Serio, M.